Examinando por Materia "Dermatomicosis"
Mostrando 1 - 1 de 1
Resultados por página
Opciones de clasificación
- PublicaciónAcceso abiertoEvaluación in vitro de la actividad antifúngica y citotóxica del eugenol y sus derivados semisintéticos frente a Trichophyton spp(Bucaramanga : Universidad de Santander, 2018, 2018-06-26) Rivera Rincón, Yohana; Leal Pinto, Sandra-MilenaDermatophytes are keratinophilic fungi that infect tissues such as skin, hair and nails in humans and animals. The treatment is based on topical, systemic and / or combined therapies with low penetrability, varied effectiveness and adverse effects that make it a challenge to research new natural bioactive molecules. The general objective was to evaluate the antifungal and cytotoxic activity in vitro of the semisynthetic compounds derived from eugenol in fungi of the genus Trichophyton. The antifungal susceptibility of twelve eugenol derivatives was evaluated against: Trichophyton mentagrophytes, Trichophyton rubrum and Trichophyton tonsurans. The MIC was determined by the microdilution method established by CLSI, subcultures from MIC, were incubated for 7 days at 30 ° C to determine MFC. In addition, the inhibition of the radial growth of the mycelium was evaluated by the substrate technique impregnated for 20 days. Likewise, in vitro toxicity in Vero cells was tested by a colorimetric assay, using the MTT tetrazolium salt. Terbinafine used as reference drug. EO, eugenol and derivatives 5,10,11 and 12 showed inhibition of T. mentagrophytes MIC 62.5-500 μg / mL and MFC 125-500 μg/mL Eugenol, derivatives 3,5 and 11 inhibited T. rubrum MIC and MFC 125-250 μg/mL EO, eugenol, compound 11 and 12 inhibited T. tonsurans with MIC and MFC 125-250 μg/mL 100% inhibition of mycelial growth of the three dermatophytes was observed after exposure with 300ug/mL and 100 ug/mL of derivatives 3,5,7-12 and 3, 7-9,12, respectively. Low toxicity in Vero cells was observed (CC50 54.06- <300 ug/mL). New bioactive molecules with antifungal effect and low in vitro toxicity are presented, which represents an advance in the pre-clinical process of development and research of new antifungal agents.